Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
6.53
-0.29 (-4.32%)
At close: Apr 28, 2026, 4:00 PM EDT
6.40
-0.13 (-1.99%)
After-hours: Apr 28, 2026, 7:11 PM EDT
Verrica Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Verrica Pharmaceuticals stock has a target of 17, which predicts an increase of 160.34% from the current stock price of 6.53.
Analyst Consensus: Buy
* Price targets were last updated on Dec 18, 2025.
Analyst Ratings
The average analyst rating for Verrica Pharmaceuticals stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 4 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Brookline Capital | Brookline Capital | Hold → Strong Buy Upgrades $17 | Hold → Strong Buy | Upgrades | $17 | +160.34% | Dec 18, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | May 14, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 8, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 12, 2025 |
Financial Forecast
Revenue This Year
25.33M
from 35.58M
Decreased by -28.81%
Revenue Next Year
49.25M
from 25.33M
Increased by 94.44%
EPS This Year
-1.37
from -1.68
EPS Next Year
-0.43
from -1.37
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 31.5M | 69.5M | ||||||
| Avg | 25.3M | 49.2M | ||||||
| Low | 18.1M | 20.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -11.5% | 174.5% | ||||||
| Avg | -28.8% | 94.4% | ||||||
| Low | -49.2% | -18.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.04 | 0.23 | ||||||
| Avg | -1.37 | -0.43 | ||||||
| Low | -1.50 | -1.04 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.